Revolutionizing drug development
Our scientists are leveraging the "digital twins"-technology to revolutionize biotherapeutic drug development.
Search
Research ruminant animal health well-being
Boehringer Ingelheim supports young scientists and veterinarians dedicated to ruminant health research
TwistPak Mixing platform for swine vaccines
TwistPak® allows for fresh mixing of Ingelvac CircoFLEX® and Ingelvac MycoFLEX® on farm in less than 5 seconds
Boehringer Ingelheim Academy
Find out more about our networking and educational initiative
2018 Animal Welfare Medals
2018 Animal Welfare Medals: Boehringer Ingelheim recognizes outstanding research in cattle, equine, swine, as well as small animals and pet categories
FIBRONEER™ Ph3 trials in patients with IPF & other PF-ILDs
Donald Zoz, M.D., Director and Senior Clinical Program Leader for Pulmonary Fibrosis, discusses the FIBRONEER™ global clinical program
Eugene Zalmover
Learn how Eugene’s work paved the way for digital innovation in Patient Safety.
Odile Bain Memorial Prize 2021
Brilliant early-career scientists in parasitology recognized
Driving environmental solutions for people and planet
In 2022, Boehringer Ingelheim's MORE GREEN environmental sustainability initiative has reached new milestones driving our global decarbonization efforts
Combating complex diseases with data
How does big data create disrupting insights for our company? Read about potential use cases and promoting a data mindset
Partnering in Retinal Health
Our partnering interests in retinal diseases offer opportunities for collaboration to complement our pipeline and advance treatment and delivery.
Collaboration Boehringer Ingelheim Veeva technology
Boehringer Ingelheim selects Veeva Development Cloud worldwide to bring innovative therapies to patients faster
Boehringer Ingelheim acquires a stake in SoundTalks
Boehringer Ingelheim acquires stake in SoundTalks NV, begins pilot programme
Information Technology
IT
Risk of parasites in dogs
With our Parassess free online tool checker, you can assess the local parasite risks for your dog so you can protect them better.
FDA- HFpEF-breakthrough-designation-EMPEROR-preserved
U.S. FDA issues Breakthrough Therapy Designation for the treatment of adults with heart failure with preserved ejection fraction
BIVF funding more than doubled to 250 M€
Boehringer Ingelheim increases funding for its corporate venture fund, the Boehringer Ingelheim Venture Fund (BIVF), from EUR 100 to 250 million
Brightline-1 trial launch in rare sarcoma
Mehdi Lahmar discusses “Brightline-1”, and our commitment to patients with Dedifferentiated Liposarcoma (DDLPS).
inauguration_biopharmaceutical_production_facility_vienna
The state-of-the-art biopharmaceutical production facility in Vienna is the single largest investment in the company's history.
Pets
Pets
Parasiticides
Parasiticides
IL-11 inhibitor antibody clinical development launched
Boehringer Ingelheim has launched clinical development of its first-in-class IL-11 inhibitor antibody as a fibrotic disease treatment
World Recycling Day: Closing the Loop
Transitioning the economy from a linear to a circular approach herculean task – but also an innovation that carries huge potential
A career at the intersection of science and marketing
A member of the Animal Health digital marketing team, our colleague Missy talks about her purpose to bring transformative technologies to the vet community